vs
Side-by-side financial comparison of B&G Foods, Inc. (BGS) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
B&G Foods, Inc. is the larger business by last-quarter revenue ($439.3M vs $346.4M, roughly 1.3× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs -4.4%, a 32.4% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs -4.7%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $-70.7M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -12.8%).
B&G Foods, Inc. is an American branded foods holding company based in Parsippany, New Jersey. The company was formed in 1996 to acquire Bloch & Guggenheimer, a Manhattan-based producer of pickles, relish and condiments which had been founded in 1889.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
BGS vs HAE — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $439.3M | $346.4M |
| Net Profit | $-19.1M | $97.3M |
| Gross Margin | 22.5% | 57.2% |
| Operating Margin | 2.5% | 36.1% |
| Net Margin | -4.4% | 28.1% |
| Revenue YoY | -4.7% | 4.8% |
| Net Profit YoY | -356.5% | — |
| EPS (diluted) | $-0.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | — | $339.0M | ||
| Q3 25 | $439.3M | $327.3M | ||
| Q2 25 | $424.4M | $321.4M | ||
| Q1 25 | $425.4M | $330.6M | ||
| Q4 24 | $551.6M | $348.5M | ||
| Q3 24 | $461.1M | $345.5M | ||
| Q2 24 | $444.6M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | — | $44.7M | ||
| Q3 25 | $-19.1M | $38.7M | ||
| Q2 25 | $-9.8M | $34.0M | ||
| Q1 25 | $835.0K | $58.0M | ||
| Q4 24 | $-222.4M | $37.5M | ||
| Q3 24 | $7.5M | $33.8M | ||
| Q2 24 | $3.9M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | 22.5% | 59.5% | ||
| Q2 25 | 20.5% | 59.8% | ||
| Q1 25 | 21.2% | 58.4% | ||
| Q4 24 | 21.5% | 55.5% | ||
| Q3 24 | 22.2% | 54.2% | ||
| Q2 24 | 20.7% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | 2.5% | 17.9% | ||
| Q2 25 | 5.2% | 16.8% | ||
| Q1 25 | 8.4% | 21.6% | ||
| Q4 24 | -46.6% | 16.9% | ||
| Q3 24 | 11.1% | 15.0% | ||
| Q2 24 | 9.9% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | — | 13.2% | ||
| Q3 25 | -4.4% | 11.8% | ||
| Q2 25 | -2.3% | 10.6% | ||
| Q1 25 | 0.2% | 17.5% | ||
| Q4 24 | -40.3% | 10.8% | ||
| Q3 24 | 1.6% | 9.8% | ||
| Q2 24 | 0.9% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | $-0.24 | $0.81 | ||
| Q2 25 | $-0.12 | $0.70 | ||
| Q1 25 | $0.01 | $1.17 | ||
| Q4 24 | $-2.81 | $0.74 | ||
| Q3 24 | $0.09 | $0.66 | ||
| Q2 24 | $0.05 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.9M | $245.4M |
| Total DebtLower is stronger | $2.0B | $1.2B |
| Stockholders' EquityBook value | $470.7M | $796.3M |
| Total Assets | $2.9B | $2.4B |
| Debt / EquityLower = less leverage | 4.30× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | $60.9M | $296.4M | ||
| Q2 25 | $54.1M | $292.9M | ||
| Q1 25 | $61.2M | $306.8M | ||
| Q4 24 | $50.6M | $320.8M | ||
| Q3 24 | $54.7M | $299.3M | ||
| Q2 24 | $40.3M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $2.0B | $1.2B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $2.0B | $1.2B | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.0B | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | — | $911.5M | ||
| Q3 25 | $470.7M | $849.2M | ||
| Q2 25 | $501.4M | $882.3M | ||
| Q1 25 | $513.1M | $820.8M | ||
| Q4 24 | $524.8M | $906.9M | ||
| Q3 24 | $755.3M | $878.9M | ||
| Q2 24 | $765.0M | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | $2.9B | $2.4B | ||
| Q2 25 | $2.9B | $2.5B | ||
| Q1 25 | $3.0B | $2.5B | ||
| Q4 24 | $3.0B | $2.5B | ||
| Q3 24 | $3.4B | $2.5B | ||
| Q2 24 | $3.4B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | 4.30× | 1.44× | ||
| Q2 25 | 3.97× | 1.39× | ||
| Q1 25 | 3.91× | 1.49× | ||
| Q4 24 | 3.85× | — | ||
| Q3 24 | 2.75× | — | ||
| Q2 24 | 2.67× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-64.6M | $293.2M |
| Free Cash FlowOCF − Capex | $-70.7M | $209.9M |
| FCF MarginFCF / Revenue | -16.1% | 60.6% |
| Capex IntensityCapex / Revenue | 1.4% | 9.5% |
| Cash ConversionOCF / Net Profit | — | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $54.8M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | — | $93.6M | ||
| Q3 25 | $-64.6M | $111.3M | ||
| Q2 25 | $17.8M | $17.4M | ||
| Q1 25 | $52.7M | $116.6M | ||
| Q4 24 | $80.3M | $43.8M | ||
| Q3 24 | $4.2M | $48.8M | ||
| Q2 24 | $11.3M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | $-70.7M | $106.3M | ||
| Q2 25 | $11.5M | $13.6M | ||
| Q1 25 | $42.4M | $100.9M | ||
| Q4 24 | $71.7M | $35.2M | ||
| Q3 24 | $-679.0K | $39.4M | ||
| Q2 24 | $5.2M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | -16.1% | 32.5% | ||
| Q2 25 | 2.7% | 4.2% | ||
| Q1 25 | 10.0% | 30.5% | ||
| Q4 24 | 13.0% | 10.1% | ||
| Q3 24 | -0.1% | 11.4% | ||
| Q2 24 | 1.2% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | 1.4% | 1.5% | ||
| Q2 25 | 1.5% | 1.2% | ||
| Q1 25 | 2.4% | 4.7% | ||
| Q4 24 | 1.6% | 2.5% | ||
| Q3 24 | 1.0% | 2.7% | ||
| Q2 24 | 1.4% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 63.17× | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | 0.56× | 1.44× | ||
| Q2 24 | 2.87× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGS
| Specialty Segment | $150.5M | 34% |
| Meals Segment | $110.0M | 25% |
| Spices And Flavor Solutions Segment | $101.4M | 23% |
| Frozen And Vegetables Segment | $77.4M | 18% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
